ATE388707T1 - Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen - Google Patents

Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen

Info

Publication number
ATE388707T1
ATE388707T1 AT00932162T AT00932162T ATE388707T1 AT E388707 T1 ATE388707 T1 AT E388707T1 AT 00932162 T AT00932162 T AT 00932162T AT 00932162 T AT00932162 T AT 00932162T AT E388707 T1 ATE388707 T1 AT E388707T1
Authority
AT
Austria
Prior art keywords
tramadol
bimodally
analgesic
opioid agonist
acting opioid
Prior art date
Application number
AT00932162T
Other languages
English (en)
Inventor
Stanley Crain
Ke-Fei Shen
Barry Sherman
Mary Remien
Remi Barbier
Nadav Friedmann
Original Assignee
Pain Therapeutics Inc
Einstein Coll Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pain Therapeutics Inc, Einstein Coll Med filed Critical Pain Therapeutics Inc
Application granted granted Critical
Publication of ATE388707T1 publication Critical patent/ATE388707T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00932162T 1999-05-06 2000-05-05 Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen ATE388707T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/306,164 US20010006967A1 (en) 1992-09-21 1999-05-06 Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists

Publications (1)

Publication Number Publication Date
ATE388707T1 true ATE388707T1 (de) 2008-03-15

Family

ID=23184116

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00932162T ATE388707T1 (de) 1999-05-06 2000-05-05 Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen

Country Status (8)

Country Link
US (1) US20010006967A1 (de)
EP (1) EP1178803B1 (de)
JP (1) JP2002544160A (de)
AT (1) ATE388707T1 (de)
AU (1) AU782533B2 (de)
CA (1) CA2373348A1 (de)
DE (1) DE60038290D1 (de)
WO (1) WO2000067739A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1041987B1 (de) 1997-12-22 2006-04-19 Euro-Celtique S.A. Peroral zu verabreichende arzneiform enthaltend eine kombination von einem opioid agonisten und naltrexon
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
ITMI20010907A1 (it) * 2001-05-02 2002-11-02 Valpharma Sa Impiego di antagonisti oppioidi per la prevenzione ed il controllo degli effetti collaterali prodotti dagli oppioidi
CA2446738C (en) * 2001-05-11 2012-05-29 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
EP1387673B1 (de) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Opioid enthaltende arzneiform gegen missbrauch
SI1416842T1 (sl) 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20060177381A1 (en) * 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
HUE032656T2 (en) 2002-04-05 2017-10-30 Euro Celtique Sa Pharmaceutical composition containing oxicodone and naloxone
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP1684764A2 (de) * 2003-10-09 2006-08-02 Inverseon, Inc. Verfahren zur behandlung von erkrankungen und zuständen mit inversen agonisten und zur untersuchung auf mittel, die als inverse agonisten wirken
US20070276024A1 (en) * 2003-10-09 2007-11-29 Inverseon , Inc. Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
AU2005282379B8 (en) 2004-09-08 2012-04-05 Spinal Modulation Inc. Neurostimulation methods and systems
US20120277839A1 (en) 2004-09-08 2012-11-01 Kramer Jeffery M Selective stimulation to modulate the sympathetic nervous system
US9205261B2 (en) 2004-09-08 2015-12-08 The Board Of Trustees Of The Leland Stanford Junior University Neurostimulation methods and systems
US7528175B2 (en) * 2004-10-08 2009-05-05 Inverseon, Inc. Method of treating airway diseases with beta-adrenergic inverse agonists
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
WO2007120864A2 (en) * 2006-04-14 2007-10-25 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
EP1897543A1 (de) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine-Waffel zur Substitutionstherapie
CN101573150B (zh) 2006-12-06 2012-03-14 脊髓调制公司 用于刺激多个脊椎节段上的神经组织的输送装置和系统
WO2008070809A2 (en) 2006-12-06 2008-06-12 Spinal Modulation, Inc. Implantable flexible circuit leads and methods of use
WO2008070808A2 (en) 2006-12-06 2008-06-12 Spinal Modulation, Inc. Expandable stimulation leads and methods of use
CA2676804A1 (en) 2007-01-29 2008-08-07 Spinal Modulation, Inc. Sutureless lead retention features
CN101657101B (zh) * 2007-02-12 2013-12-11 Dmi生物科学公司 并存早泄和勃起功能障碍的治疗
CN101674728A (zh) * 2007-02-12 2010-03-17 Dmi生物科学公司 降低曲马多的副作用
EP2259780A2 (de) 2008-02-28 2010-12-15 Syntropharma Limited Pharmazeutische zusammensetzung mit naltrexon
CN102202729B (zh) 2008-10-27 2014-11-05 脊髓调制公司 选择性刺激系统和用于医疗状况的信号参数
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2010111358A2 (en) 2009-03-24 2010-09-30 Spinal Modulation, Inc. Pain management with stimulation subthreshold to parasthesia
CA2761778A1 (en) 2009-05-15 2010-11-18 Spinal Modulation, Inc. Methods, systems and devices for neuromodulating spinal anatomy
WO2011087755A2 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
US20110276056A1 (en) 2010-05-10 2011-11-10 Grigsby Eric J Methods, systems and devices for reducing migration
EP2670478B1 (de) 2011-02-02 2016-07-27 Spinal Modulation Inc. Vorrichtungen und systeme zur gezielten behandlung von bewegungsleiden
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
JP2021531299A (ja) 2018-07-23 2021-11-18 トレビ セラピューティクス インコーポレイテッド 慢性咳嗽、息切れ、及び呼吸困難の治療
KR20220127849A (ko) 2020-01-10 2022-09-20 트레비 테라퓨틱스, 인코포레이티드 날부핀의 투여 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2728240B2 (ja) * 1988-07-26 1998-03-18 ヘキスト薬品工業株式会社 ヒトプロテインｃ変異体及びその製造方法

Also Published As

Publication number Publication date
JP2002544160A (ja) 2002-12-24
EP1178803B1 (de) 2008-03-12
AU782533B2 (en) 2005-08-04
WO2000067739A2 (en) 2000-11-16
AU4992800A (en) 2000-11-21
CA2373348A1 (en) 2000-11-16
WO2000067739A3 (en) 2001-01-25
US20010006967A1 (en) 2001-07-05
EP1178803A2 (de) 2002-02-13
DE60038290D1 (de) 2008-04-24

Similar Documents

Publication Publication Date Title
ATE388707T1 (de) Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen
EP1539234A4 (de) Verfahren zur prävention oder behandlung von zellmalignität durch verabreichung von cd2-antagonisten
ATE446751T1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
WO2001037785A3 (en) Novel methods and compositions involving opioids and antagonists thereof
MXPA04008772A (es) Composiciones de clorhidrato de naltrexona.
ATE414515T1 (de) Medikamente zur gleichzeitigen erhöhung der analgetischen wirksamkeit und verminderung des abhängigkeitspotentials, die durch exogene und endogene opioidagonisten verursacht werden
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
WO2005041891A3 (en) Neutrophil activation by immune response modifier compounds
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
MXPA05003501A (es) Metodos para tratamiento del dolor administrando un antagonista del factor de crecimiento del nervio y un analgesico opioide y composiciones que los contienen.
CO4410317A1 (es) Combinacion y conjuntos farmaceuticos de un antagonista o- pioide y un inhibidor de recaptacion selectiva de serotoni- na, y el tratamiento de alcoholismo y dependencia alcoholica empleando los mismos.
IL162616A0 (en) Tetrahydroquinoline analogues as muscarinic agonists
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO2002043807A3 (en) Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
EA200001112A1 (ru) Безводные и моногидратные формы n- (3-этинилфениламино)-6,7- бис (2-метоксиэтокси)-4-хиназолинамина мезилата
MXPA03009595A (es) Uso de antagonistas del canal de sodio neuronal para control de ectoparasitos de animales homeotermicos.
EP1262196A3 (de) Kombination eines Inhibitoren der Monoaminwiederaufnahme und eines Opioidanatagonisten zur Verwendung in Alkoholismus und Alkoholsucht
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
WO2007056142A3 (en) Methods of preventing the serotonin syndrome and compositions for use therefor
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
EA200401137A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
DE60015187D1 (de) Urotensin-ii rezeptorantagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties